DXCM: Kirby McInerney LLP Advises DexCom, Inc. Investors of Class Action Lawsuit

Core Viewpoint - The article discusses a securities fraud class action lawsuit against DexCom, Inc. related to misleading statements and undisclosed risks associated with its G6 and G7 glucose monitoring devices, which allegedly posed health risks to users [3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, alleging that the company made unauthorized design changes to its G6 and G7 devices, compromising their reliability and safety [3]. - Allegations include that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of health risks associated with them [3]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, leading to a share price decline of approximately 9.15%, from $77.84 to $70.72 [4]. - The FDA's published warning on March 25, 2025, indicated that the G6 and G7 devices were "adulterated" due to unauthorized modifications, causing inaccuracies that increased health risks for users, resulting in a further share price drop of about 2.4% [5]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating from "outperform" to "perform," citing rising concerns about the G7's accuracy and performance, which led to a share price decline of approximately 3.1% [6]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks linked to the G7 devices, including hospitalizations and fatalities, causing a significant share price drop of about 11% [7].